29 April 2016 - Thousands of women will benefit from subsidised access to the breast cancer drug Tamoxifen which has been added to the Pharmaceutical Benefits Scheme (PBS), clinicians say.

The drug Nolvadex, also known generically as tamoxifen citrate, is a well-established drug for certain breast cancers and aims to reduce breast cancer from occurring in women at high risk.

The listing is the first medicine for the prevention of cancer on the PBS, and is expected to benefit an anticipated 250,000 women.

Professor John Forbes AM, director of research for the Australian New Zealand Breast Cancer Trials Group, said it was further recognition of the importance of clinical trials research.

For more details, go to: http://www.theherald.com.au/story/3879021/breast-cancer-prevention-drug-on-pbs/